Actimed Therapeutics
PrivateLast Round
Series A
Aug 22, 2023
Total Funding Raised
$35.51M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Actimed Therapeutics operates in Healthcare & Life Sciences and is based in Ascot. Its latest recorded funding round was a Series A round in August 2023.
Actimed Therapeutics is a clinical-stage specialty pharmaceutical company focused on bringing innovation to the treatment of cancer cachexia and other muscle wasting disorders.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Actimed Therapeutics Comparables
Compare Actimed Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Endevica Bio | 80% | |
| SynDevRx | 79% | |
| Pephexia Therapeutics | 79% |
For institutional investors. Book with your work email.
Actimed Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Aug 22, 2023 | ||||
| Series A | Jun 26, 2023 | ||||
| Seed | Jan 4, 2023 | ||||
| Seed | Jun 10, 2021 | ||||
| Corporate Funding | Apr 13, 2021 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 20, 2026
Monthly visitors grew 193% MoM.
- May 16, 2026
Monthly visitors increased 261% MoM, reaching 1.4K.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- ends_partnership_withAug 6, 2026
On Aug 6th '26, Actimed Therapeutics ends its rights deal with Faraday Pharmaceuticals, Inc. for S-oxprenolol, regaining full worldwide development, manufacturing and commercialization rights and strategic control of the asset.
- invests_into_assetsAug 6, 2026
Actimed Therapeutics reacquires exclusive global development, manufacturing, and commercialization rights to S-oxprenolol from Faraday Pharmaceuticals in United Kingdom on Aug 6th '26, restoring full strategic control over the asset.
For institutional investors. Book with your work email.
Actimed Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Actimed Therapeutics's valuation, stock price, and market status.
Is Actimed Therapeutics a public or private company?
Actimed Therapeutics is a private company.
What is the current stock price of Actimed Therapeutics?
Actimed Therapeutics is a private company, so its shares have no public market price. Caplight tracks Actimed Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Actimed Therapeutics worth (valuation)?
Valuation information for Actimed Therapeutics is not publicly available.
Can I buy Actimed Therapeutics stock?
Actimed Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Actimed Therapeutics's last funding round?
Actimed Therapeutics's most recent funding round was Series A on August 22, 2023.
Who are the main investors in Actimed Therapeutics?
Investor information for Actimed Therapeutics is not publicly disclosed.
Will Actimed Therapeutics IPO soon?
No public IPO plans have been announced for Actimed Therapeutics.
How can I track Actimed Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Actimed Therapeutics's shares on secondary markets.